<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19088">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858401</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-382-1450</org_study_id>
    <nct_id>NCT02858401</nct_id>
  </id_info>
  <brief_title>Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults</brief_title>
  <official_title>A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and tolerability of a 6-dose
      regimen of vesatolimod (formerly GS-9620) (at 1 mg, 2 mg, and 4 mg dose levels) in HIV-1
      infected virologically suppressed adults on antiretroviral therapy (ART) and to evaluate the
      virologic effect of vesatolimod as measured by changes in plasma HIV-1 RNA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent serious adverse events (SAEs) and all treatment-emergent adverse events</measure>
    <time_frame>Up to 157 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum change from baseline in plasma log10 HIV-1 RNA at any postdose timepoint</measure>
    <time_frame>Up to Day 81 (Cohorts 1 to 3) or up to Day 134 (Cohort 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma log10 HIV-1 RNA at post-baseline visits</measure>
    <time_frame>Up to 157 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with plasma HIV-1 RNA &gt; 50 copies/mL at any postdose timepoint</measure>
    <time_frame>Up to Day 81 (Cohorts 1 to 3) or up to Day 134 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in single copy assay (SCA) from predose to 2 days postdose</measure>
    <time_frame>Predose to 2 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cell-associated HIV-1 RNA from predose to 2 days postdose</measure>
    <time_frame>Predose to 2 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the HIV latent reservoirs (Cohort 4 only)</measure>
    <time_frame>Up to Day 134</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Vesatolimod 1 mg (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vesatolimod 2 mg (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vesatolimod 4 mg (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vesatolimod 6 mg (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohorts 1-4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 71 or 127 days, while continuing their existing ARV regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesatolimod</intervention_name>
    <description>Tablet(s) administered orally once every 2 weeks</description>
    <arm_group_label>Vesatolimod 1 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Vesatolimod 2 mg (Cohort 2)</arm_group_label>
    <arm_group_label>Vesatolimod 4 mg (Cohort 3)</arm_group_label>
    <arm_group_label>Vesatolimod 6 mg (Cohort 4)</arm_group_label>
    <other_name>GS-9620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet(s) administered orally once every 2 weeks</description>
    <arm_group_label>Placebo (Cohorts 1-4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARV regimen</intervention_name>
    <description>Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.</description>
    <arm_group_label>Vesatolimod 1 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Vesatolimod 2 mg (Cohort 2)</arm_group_label>
    <arm_group_label>Vesatolimod 4 mg (Cohort 3)</arm_group_label>
    <arm_group_label>Vesatolimod 6 mg (Cohort 4)</arm_group_label>
    <arm_group_label>Placebo (Cohorts 1-4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  HIV-1 infection

          -  Aged ≥ 18 years at Pre-baseline/Day -13

          -  On antiretroviral (ARV) treatment for ≥ 12 consecutive months prior to
             Pre-Baseline/Day -13

               -  The following agents are allowed as part of the current ARV regimen: NRTIs,
                  raltegravir, dolutegravir, rilpivirine, and maraviroc

               -  The following agents are NOT allowed as part of the current ARV regimen: HIV
                  protease inhibitors (including low dose ritonavir), cobicistat-containing
                  regimens, elvitegravir, efavirenz, etravirine, and nevirapine

               -  A change in ARV regimen ≥ 60 days prior to baseline/Day 1 for reasons other than
                  virologic failure (eg, tolerability, simplification, drug-drug interaction
                  profile) is allowed

          -  Plasma HIV-1 RNA &lt; 50 copies/mL at screening

          -  Documented plasma HIV-1 RNA levels &lt; 50 copies/mL (according to the local assay being
             used) for ≥ 12 months preceding the screening visit (measured at least twice using a
             licensed assay with a lower limit of quantitation of at least 40 copies/mL)

               -  Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable
                  viremia, or &quot;blip&quot;) prior to screening are acceptable. (If the lower limit of
                  detection of the local HIV-1 RNA assay is &lt; 50 copies/mL, the plasma HIV-1 RNA
                  level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests)

               -  If ART regimen is changed ≥ 60 days prior to Pre-Baseline/Day -13, plasma HIV-1
                  RNA &lt;50 copies/mL at Pre-baseline/Day -13 visit is required.

          -  No documented history of resistance to any components of the current ARV regimen

          -  Availability of a fully active alternative ARV regimen, in the opinion of the
             Investigator, in the event of discontinuation of the current ARV regimen with
             development of resistance.

          -  Hgb ≥ 11.5 g/dL (males) or ≥ 11 g/dL (females)

          -  White blood cells (WBC) ≥ 2,500 cells/μL

          -  Platelets ≥ 125,000/mL

          -  Absolute neutrophil count (ANC) ≥ 1000 cells/μL

          -  CD4 count ≥ 300 cells/μL

          -  Albumin ≥ 3.9 g/dL

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit
             of the normal range (ULN)

          -  Estimated glomerular filtration rate ≥ 60 mL/min

          -  No autoimmune disease

        Key Exclusion Criteria:

          -  Hepatitis B surface antigen (HBsAg) positive

               -  Positive anti-HBs antibody and negative HBsAg results are acceptable

          -  Hepatitis C antibody (HCVAb) positive

               -  Positive anti-HCV antibody and negative HCV polymerase chain reaction (PCR)
                  results are acceptable

          -  Documented history of pre-ART CD4 nadir &lt; 100 cells/µL

               -  Unknown pre-ART CD4 nadir is acceptable

          -  A new AIDS-defining condition diagnosed within 90 days prior to screening

          -  Acute febrile illness within 35 days prior to pre-baseline/Day -13

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Mills, MD</last_name>
      <phone>310-550-2271</phone>
      <email>tmills@tonymillsmd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constance A Benson, MD</last_name>
      <phone>619-543-8080</phone>
      <email>cbenson@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Infectious Diseases Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael F. Para, MD</last_name>
      <phone>614-293-5282</phone>
      <email>para.1@osu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Anne Riddler, MD</last_name>
      <phone>412-383-1741</phone>
      <email>riddler@pitt.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>July 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
